Research Papers:
RUNX1 promote invasiveness in pancreatic ductal adenocarcinoma through regulating miR-93
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1569 views | HTML 3304 views | ?
Abstract
Yin Cheng1, Haiyan Yang1, Yang Sun1, Hongkai Zhang1, Shuangni Yu1, Zhaohui Lu1 and Jie Chen1
1Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Correspondence to:
Jie Chen, email: [email protected]
Keywords: pancreatic ductal adenocarcinoma (PDAC); miR-93; RUNX1; HMGA2 (High mobility group AT-hook 2); tumor progression
Received: June 13, 2017 Accepted: July 26, 2017 Published: August 24, 2017
ABSTRACT
Runt-related transcription factor 1(RUNX1), a key factor in hematopoiesis that mediates specification and homeostasis of hematopoietic stem and progenitor cells (HSPCs), is also overexpressed in several solid human cancers, and correlated with tumor progression. However, the expression and function of RUNX1 in pancreatic ductal adenocarcinoma were still unclear. Here, we show that RUNX1 is highly expressed in pancreatic adenocarcinoma tissues and knocking down of RUNX1 attenuated aggressiveness in pancreatic cell lines. Moreover, we found that RUNX1 could negatively regulate the expression of miR-93. Bioinformatics method showed that there are two binding sites in the the promotor region of miR-93 precursor and through ChIP-qPCR and firefly luciferase reporter assay, we vertified that these two binding sites each have transcriptive activity in one pancreatic cell lines. This result supported our presumption that RUNX1 regulate miR-93 through binding to the promotor region of miR-93. Besides, the expression and function of miR-93 is quite the opposite, miR-93 overexpression suppresses migration and invasiveness in pancreatic cell lines supporting that RUNX1 negatively regulated miR-93. Our findings provided evidence regarding the role of RUNX1 as an oncogene through the inhibition of miR-93. Targeting RUNX1 can be a potential therapeutic strategy in pancreatic cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20433